2231258-73-2
2231258-73-2
Chemical Structure
Adakitug
Synonym(s): BMS-986253; HuMax-IL-8
- CAS No.: 2231258-73-2
- Formula:N/A
- Molecular Weight:(144.94 kDa)
SMILES: [Adakitug]
Biological Activity: Adakitug (BMS-986253) is a CHO-expressed human antibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Adakitug exhibits anti-tumor activity and can be applied in tumor research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Adakitug | ≥99.0% | Adakitug (BMS-986253) is a CHO-expressed human antibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Adakitug exhibits anti-tumor activity and can be applied in tumor research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Marijo Bilusic, et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019 Sep 5;7(1):240. [Content Brief]
- [2]. Davar D, et al. 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L) 1–experienced patients with advanced cancer: initial phase 1 results. 2020.
